Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy

Cancer

Volumn 106, Issue 3, 2006, Pages 581-588

  Basaria, Shehzad ^a,b   Muller, Denis C ^b   Carducci, Michael A ^c   Egan, Josephine ^b   Dobs, Adrian S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Androgen deprivation therapy; Cardiovascular disease; Hyperglycemia; Hypogonadism; Insulin resistance

Indexed keywords

ANDROGEN; ANTIANDROGEN; GLUCOSE; INSULIN; LEPTIN; TESTOSTERONE;

AGED; ARTICLE; BODY MASS; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; EVALUATION; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HOMEOSTASIS; HOMEOSTATIC MODEL ASSESSMENT; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METASTASIS; MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK ASSESSMENT; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; UNITED STATES;

AGED; ANDROGEN ANTAGONISTS; BLOOD GLUCOSE; BODY MASS INDEX; CARCINOMA; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 31544440178     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21642     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
2. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
3. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-1788.
4. Basaria S, Lieb J 2nd, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxford). 2002;56:779-786.
5. Haffher SM, Shaten J, Stern MP, et al. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. Am J Epidemiol. 1996;143:889-897.
6. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002;25:55-60.
7. Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992;16:991-997.
8. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261-4267.
9. Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83:1180-1188.
10. Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest. 1983;71:1523-1535.
11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
12. Haffner SM, Valdez RA, Mykkanen L, et al. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism. 1994;43:599-603.
13. Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care. 2000;23:490-494.
14. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036-1041.
15. Bjorntorp P. The android woman-a risky condition. J Intern Med. 1996;239:105-110.
16. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab. 1997;82:682-685.
17. Haffner SM, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994;43:212-219.
18. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand. 1992;146:505-510.
19. Sinha-Hikim I, Artaza J, Woodhouse L, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283:E154-E164.
20. Lillioja S, Young AA, Culter CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 1987;80:415-424.
21. Luukkaa V, Pesonen U, Huhtaniemi I, et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab. 1998;83:3243-3246.
22. Baumgartner RN, Waters DL, Morley JE, et al. Age-related changes in sex hormones affect the sex difference in serum leptin independently of changes in body fat. Metabolism. 1999;48:378-384.
23. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (London). 2003;104:195-201.
24. Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171:2285-2290.
25. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14:701-706.
26. Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100:1690-1696.
27. Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666-1670.
28. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313-3318.
29. Ribeiro R, Lopes C, Medeiros R. Leptin and prostate: implications for cancer prevention-overview of genetics and molecular interactions. Eur J Cancer Prev. 2004;13:359-368.
30. Hsing AW, Chua S Jr., Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001;93:783-789.
31. Hsing AW, Gao YT, Chua S Jr., et al. Insulin resistance and prostate cancer risk. J Natl Cancer Inst. 2003;95:67-71.
32. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev. 2002;3:303-308.
33. Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab. 1998;83:775-779.
34. Stattin P, Soderberg S, Hallmans G, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab. 2001;86:1341-1345.
35. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem. 2003;278:42660-42667.
36. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997;272:32686-32695.
37. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62:6659-6666.
38. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683-1686.
39. Izawa JI, Dinney CP. The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ. 2001;164:662-670.